IL148309A0 - Use of retigabine for the treatment of neuropathic pain - Google Patents

Use of retigabine for the treatment of neuropathic pain

Info

Publication number
IL148309A0
IL148309A0 IL14830900A IL14830900A IL148309A0 IL 148309 A0 IL148309 A0 IL 148309A0 IL 14830900 A IL14830900 A IL 14830900A IL 14830900 A IL14830900 A IL 14830900A IL 148309 A0 IL148309 A0 IL 148309A0
Authority
IL
Israel
Prior art keywords
retigabine
treatment
neuropathic pain
neuropathic
pain
Prior art date
Application number
IL14830900A
Other languages
English (en)
Original Assignee
Viatris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Gmbh filed Critical Viatris Gmbh
Publication of IL148309A0 publication Critical patent/IL148309A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14830900A 1999-09-27 2000-09-22 Use of retigabine for the treatment of neuropathic pain IL148309A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/406,135 US6117900A (en) 1999-09-27 1999-09-27 Use of retigabine for the treatment of neuropathic pain
PCT/EP2000/009284 WO2001022953A2 (fr) 1999-09-27 2000-09-22 Utilisation de retigabine pour le traitement de douleurs neuropathiques

Publications (1)

Publication Number Publication Date
IL148309A0 true IL148309A0 (en) 2002-09-12

Family

ID=23606675

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14830900A IL148309A0 (en) 1999-09-27 2000-09-22 Use of retigabine for the treatment of neuropathic pain
IL148309A IL148309A (en) 1999-09-27 2002-02-21 Use of retigabine to treat neopathic pain
IL187030A IL187030A (en) 1999-09-27 2007-10-30 Use of retigabine for the preparation of drugs for the treatment of non-allodinia pain, hyperalgesic pain, pseudoassay, pain due to diabetes, pain associated with sympathetic dystrophy of reflexes, vulvodynia, paraesthesia, pain due to activation of pressure and pain due to spinal cord injury

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL148309A IL148309A (en) 1999-09-27 2002-02-21 Use of retigabine to treat neopathic pain
IL187030A IL187030A (en) 1999-09-27 2007-10-30 Use of retigabine for the preparation of drugs for the treatment of non-allodinia pain, hyperalgesic pain, pseudoassay, pain due to diabetes, pain associated with sympathetic dystrophy of reflexes, vulvodynia, paraesthesia, pain due to activation of pressure and pain due to spinal cord injury

Country Status (35)

Country Link
US (1) US6117900A (fr)
EP (1) EP1223927B1 (fr)
JP (1) JP2003510273A (fr)
KR (1) KR100730829B1 (fr)
CN (2) CN101444498A (fr)
AR (1) AR026163A1 (fr)
AT (1) ATE288748T1 (fr)
AU (1) AU777764B2 (fr)
BG (1) BG65795B1 (fr)
BR (1) BR0014293A (fr)
CA (2) CA2659048A1 (fr)
CZ (1) CZ295980B6 (fr)
DE (1) DE50009504D1 (fr)
DK (1) DK1223927T3 (fr)
EE (1) EE05073B1 (fr)
ES (1) ES2237461T3 (fr)
HK (1) HK1052471A1 (fr)
HR (1) HRP20020234A2 (fr)
HU (1) HUP0202853A3 (fr)
IL (3) IL148309A0 (fr)
IS (1) IS6303A (fr)
MX (1) MXPA02003179A (fr)
NO (1) NO329744B1 (fr)
NZ (1) NZ517616A (fr)
PL (1) PL200847B1 (fr)
PT (1) PT1223927E (fr)
RS (1) RS50091B (fr)
RU (1) RU2264813C2 (fr)
SI (1) SI1223927T1 (fr)
SK (1) SK286057B6 (fr)
TR (1) TR200200706T2 (fr)
TW (1) TWI257304B (fr)
UA (1) UA72550C2 (fr)
WO (1) WO2001022953A2 (fr)
ZA (1) ZA200202449B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268353A1 (en) * 2000-06-09 2001-12-17 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
TWI287984B (en) 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
WO2002061075A1 (fr) * 2001-02-01 2002-08-08 Takeda Chemical Industries, Ltd. Proteine de recepteur couple aux proteines g et adn correspondant
CA2438868A1 (fr) 2001-02-20 2002-09-19 Valentin K. Gribkoff Modulateurs de canaux potassiques kcnq et leur utilisation dans le traitement de la migraine et de maladies liees a la migraine d'un point de vue mecanistique
AR033095A1 (es) * 2001-04-04 2003-12-03 Wyeth Corp Metodos para el tratamiento de motilidad gastrica hiperactiva
US20080039461A1 (en) * 2002-09-05 2008-02-14 Protter Andrew A Treatment of pain by inhibition of p38 map kinase
JP2006503025A (ja) * 2002-09-05 2006-01-26 サイオス インク． ｐ３８ＭＡＰキナーゼの抑制による疼痛治療
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
WO2004054511A2 (fr) * 2002-12-13 2004-07-01 The Regents Of The University Of California Traitement de la douleur avec des combinaisons de nalbuphine et d'autres agonistes de recepteurs kappa-opioides et antagonistes de recepteurs opioides
MXPA05006463A (es) * 2002-12-27 2005-08-26 Lundbeck & Co As H Derivados de 1,2,4-triaminobenceno, utiles para tratar transtornos del sistema nervioso central.
KR20050089862A (ko) * 2002-12-27 2005-09-08 하. 룬트벡 아크티에 셀스카브 중추신경계 장애의 치료에 유용한 1,2,4-트리아미노벤젠유도체
EP1631546A1 (fr) * 2003-04-25 2006-03-08 H. Lundbeck A/S Derives indole et indoline substitues
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI357901B (en) 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
EP1861394A1 (fr) 2005-03-03 2007-12-05 H.Lundbeck A/S Derives de pyridine substitues
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
BRPI0716715B1 (pt) * 2006-08-23 2021-07-06 Xenon Pharmaceuticals, Inc Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potássio, seus usos, produto, composição, comprimido e cápsula
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
CA2670966A1 (fr) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International Analogues de 1,4-diamino retigabine bicycliques en tant que modulateurs de canaux potassiques
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US8765815B2 (en) 2007-09-20 2014-07-01 Ramot At Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
US20100120906A1 (en) * 2008-07-18 2010-05-13 Valeant Pharmaceuticals International Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
DE102009013613A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
DE102009013611A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Festes Retigabin in nicht-kristalliner Form
DE102009013612A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
IT1398282B1 (it) * 2009-07-30 2013-02-22 Difass S A Ora Farmapros S P A Composizione comprendente acido alfa-lipoico e carnosina per il trattamento della sindrome dell arto fantasma
US20110087650A1 (en) * 2009-10-06 2011-04-14 Johnson Controls Technology Company Creation and use of causal relationship models in building management systems and applications
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
RU2446795C1 (ru) * 2011-03-31 2012-04-10 Федеральное государственное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Министерства здравоохранения и социального развития Российской Федерации" ФГУ "МНИОИ им. П.А. Герцена "Минздравсоцразвития России" Способ предотвращения фантомного болевого синдрома после ампутации конечностей
CN102531966B (zh) * 2011-12-23 2013-07-24 山东创新药物研发有限公司 瑞替加滨的晶型d及其制备方法
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
CN103271899A (zh) * 2012-12-30 2013-09-04 北京阜康仁生物制药科技有限公司 瑞替加滨粉碎粒度在制剂中的应用
CN105919990A (zh) * 2016-06-29 2016-09-07 青岛云天生物技术有限公司 用于预防和治疗神经病理性疼痛的药物组合物及其用途
CN106176715A (zh) * 2016-06-29 2016-12-07 青岛云天生物技术有限公司 一种神经病理性疼痛治疗用药物组合物及其用途
WO2019014547A1 (fr) 2017-07-14 2019-01-17 Texas Tech University System Carbamates de pyridine fonctionnalisés présentant une activité neuroprotectrice améliorée
CA3077659A1 (fr) 2017-10-09 2019-04-18 Ramot At Tel-Aviv University Ltd. Modulateurs de canaux trpv1 et ioniques potassiques et leurs utilisations
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
WO2021092439A1 (fr) 2019-11-08 2021-05-14 Xenon Pharmaceuticals Inc. Méthodes de traitement de troubles dépressifs
IL304920A (en) 2021-02-09 2023-10-01 Xenon Pharmaceuticals Inc A voltage-gated potassium channel opener for use in the treatment of anhedonia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use

Also Published As

Publication number Publication date
DK1223927T3 (da) 2005-04-11
CZ295980B6 (cs) 2005-12-14
ATE288748T1 (de) 2005-02-15
MXPA02003179A (es) 2003-08-20
EP1223927B1 (fr) 2005-02-09
RU2002109240A (ru) 2004-01-10
NZ517616A (en) 2002-12-20
TWI257304B (en) 2006-07-01
JP2003510273A (ja) 2003-03-18
HUP0202853A3 (en) 2003-10-28
YU20302A (sh) 2005-03-15
NO20021418D0 (no) 2002-03-21
AU777764B2 (en) 2004-10-28
RU2264813C2 (ru) 2005-11-27
PT1223927E (pt) 2005-06-30
CZ2002989A3 (cs) 2002-08-14
IL187030A0 (en) 2008-02-09
KR100730829B1 (ko) 2007-06-20
UA72550C2 (en) 2005-03-15
CN1409632A (zh) 2003-04-09
EP1223927A2 (fr) 2002-07-24
AU7906100A (en) 2001-04-30
EE05073B1 (et) 2008-10-15
HRP20020234A2 (en) 2003-06-30
IS6303A (is) 2002-03-18
HUP0202853A2 (hu) 2002-12-28
ES2237461T3 (es) 2005-08-01
WO2001022953A2 (fr) 2001-04-05
RS50091B (sr) 2009-01-22
BG106450A (en) 2002-09-30
PL353393A1 (en) 2003-11-17
BR0014293A (pt) 2002-05-21
SI1223927T1 (fr) 2005-08-31
WO2001022953A3 (fr) 2002-05-23
PL200847B1 (pl) 2009-02-27
HK1052471A1 (zh) 2003-09-19
SK2922002A3 (en) 2002-08-06
CA2384504A1 (fr) 2001-04-05
IL187030A (en) 2011-06-30
NO20021418L (no) 2002-03-21
CN101444498A (zh) 2009-06-03
BG65795B1 (bg) 2009-12-31
EE200200145A (et) 2003-04-15
CA2384504C (fr) 2009-05-26
SK286057B6 (sk) 2008-02-05
TR200200706T2 (tr) 2002-10-21
DE50009504D1 (de) 2005-03-17
CN100522155C (zh) 2009-08-05
US6117900A (en) 2000-09-12
CA2659048A1 (fr) 2001-04-05
KR20020042691A (ko) 2002-06-05
IL148309A (en) 2007-12-03
AR026163A1 (es) 2003-01-29
NO329744B1 (no) 2010-12-13
ZA200202449B (en) 2003-03-26

Similar Documents

Publication Publication Date Title
IL187030A0 (en) Use of retigabine for the treatment of neuropathic pain
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL157593A0 (en) Carbamate compounds for use in the treatment of pain
GB0213869D0 (en) The treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
GB2360453B (en) Treatment of skin conditions
CZ20011872A3 (cs) Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
GB9904252D0 (en) Composition for the treatment of pain
GB9906808D0 (en) Formulation for treatment of pain
IL150208A0 (en) Compound and method for the treatment of pain
HUP0203741A3 (en) Treatment of osteoporosis
EP1165060A4 (fr) Traitement des calculs biliaires
SI1156856T1 (sl) Uporaba fluoriniranih triazolov za zdravljenje nevropaticnih bolecin
GB9918000D0 (en) Compositions for the treatment of pain
GB9910545D0 (en) The treatment of acarids
GB0219706D0 (en) The treatment of neuropathic pain
GB9907649D0 (en) Skin treatment
GB9904918D0 (en) Skin treatment
GB9914101D0 (en) Treatment of oils
GB9914103D0 (en) Treatment of oils
GB9914106D0 (en) Treatment of oils
GB0216978D0 (en) The treatment of pain
GB9901904D0 (en) RTherapeutic use of human pheramones
GB0213870D0 (en) The treatment of pain conditions

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed